58.00
price up icon1.36%   0.6215
 
loading

Incyte Corp Borsa (INCY) Ultime notizie

pulisher
11:16 AM

Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting | INCY Stock News - GuruFocus

11:16 AM
pulisher
11:03 AM

Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Yahoo Finance

11:03 AM
pulisher
Apr 22, 2025

Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth - MSN

Apr 22, 2025
pulisher
Apr 22, 2025

Cytokine Release Syndrome Treatment Market Size in 7MM - openPR.com

Apr 22, 2025
pulisher
Apr 20, 2025

Incyte (INCY) Sees Boosted Price Target by BofA Analyst | INCY Stock News - GuruFocus

Apr 20, 2025
pulisher
Apr 19, 2025

Lobbying Update: $60,000 of INCYTE CORPORATION lobbying was just disclosed - Nasdaq

Apr 19, 2025
pulisher
Apr 18, 2025

Incyte Grants Restricted Stock Units to New Employees - MSN

Apr 18, 2025
pulisher
Apr 18, 2025

Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market - GlobeNewswire Inc.

Apr 18, 2025
pulisher
Apr 17, 2025

Incyte Can Get Novartis' Privileged Info On Drug Royalty Deal - Law360

Apr 17, 2025
pulisher
Apr 16, 2025

Incyte Earnings Preview: What to Expect - Nasdaq

Apr 16, 2025
pulisher
Apr 16, 2025

Incyte Earnings Preview: What To Expect - Barchart.com

Apr 16, 2025
pulisher
Apr 15, 2025

Incyte to Announce Q1 2025 Financial Results on April 29 - MSN

Apr 15, 2025
pulisher
Apr 14, 2025

Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch

Apr 14, 2025
pulisher
Apr 13, 2025

Incyte (INCY) Revenue Surges, But Stock Drops 20% - GuruFocus

Apr 13, 2025
pulisher
Apr 11, 2025

Global Janus Kinase Inhibitors Market Surges at 8.4% CAGR - openPR.com

Apr 11, 2025
pulisher
Apr 11, 2025

Incyte to Report First Quarter Financial Results | INCY Stock Ne - GuruFocus

Apr 11, 2025
pulisher
Apr 10, 2025

Incyte to Report First Quarter Financial Results - Business Wire

Apr 10, 2025
pulisher
Apr 09, 2025

Judges Skeptical of Incyte's Patent Block on Sun's Alopecia Drug - Bloomberg Law News

Apr 09, 2025
pulisher
Apr 09, 2025

Skeptical Panel Probes Incyte Block on Sun’s Alopecia Drug (1) - Bloomberg Law News

Apr 09, 2025
pulisher
Apr 08, 2025

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 7, 2025 - BioSpace

Apr 08, 2025
pulisher
Apr 07, 2025

Incyte Can't Get Pretrial Win In Novartis Royalty Fight - Law360

Apr 07, 2025
pulisher
Apr 07, 2025

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY) - Yahoo Finance

Apr 07, 2025
pulisher
Apr 03, 2025

Incyte Co. (NASDAQ:INCY) Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat

Apr 03, 2025
pulisher
Apr 02, 2025

Follicular Lymphoma Market to Reach New Heights in Growth - openPR.com

Apr 02, 2025
pulisher
Apr 02, 2025

Follicular Lymphoma Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Roche, BeiGene, Kite Pharma, Incyte Corp, AstraZeneca, MEI Pharma, Novartis, Innovent Biologics, Regeneron - Barchart.com

Apr 02, 2025
pulisher
Apr 02, 2025

1,764,725 Shares in Incyte Co. (NASDAQ:INCY) Acquired by Norges Bank - MarketBeat

Apr 02, 2025
pulisher
Apr 01, 2025

Incyte Stock: Is INCY Outperforming the Health Care Sector? - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Incyte Stock: Is INCY Outperforming The Health Care Sector? - Barchart.com

Apr 01, 2025
pulisher
Apr 01, 2025

3 Reasons INCY is Risky and 1 Stock to Buy Instead - Yahoo Finance

Apr 01, 2025
pulisher
Mar 31, 2025

Women in healthcare and life sciences - The Business Journals

Mar 31, 2025
pulisher
Mar 31, 2025

Incyte’s SWOT analysis: stock faces patent cliff challenge amid pipeline promise - Investing.com

Mar 31, 2025
pulisher
Mar 30, 2025

Meiji Yasuda Asset Management Co Ltd. Purchases 32,830 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat

Mar 30, 2025
pulisher
Mar 30, 2025

Incyte : U.S. FDA allows Lilly's COVID-19 drug to be taken without remdesivir - MarketScreener

Mar 30, 2025
pulisher
Mar 27, 2025

Incyte Announces Positive Phase 3 Results for Hidradenitis Suppurativa Treatment - MSN

Mar 27, 2025
pulisher
Mar 26, 2025

Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch

Mar 26, 2025
pulisher
Mar 24, 2025

Incyte Had a Bad Week. Investors Are Used to It. - MSN

Mar 24, 2025
pulisher
Mar 24, 2025

Leerink Partners Adjusts Price Target on Incyte to $92 From $100, Maintains Outperform Rating - MarketScreener

Mar 24, 2025
pulisher
Mar 24, 2025

Incyte’s Hold Rating: Balancing Pipeline Challenges and Established Product Valuation - TipRanks

Mar 24, 2025
pulisher
Mar 23, 2025

Compass Ion Advisors LLC Has $960,000 Position in Incyte Co. (NASDAQ:INCY) - MarketBeat

Mar 23, 2025
pulisher
Mar 22, 2025

Monday.com, Incyte, Lucid, Bloom, EQT: Trending by Analysts - TipRanks

Mar 22, 2025
pulisher
Mar 21, 2025

Why Incyte Stock Was Tanking This Week - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Incyte (INCY) Stock Declines Due to Clinical Trial Results - GuruFocus.com

Mar 21, 2025
pulisher
Mar 21, 2025

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance

Mar 21, 2025
pulisher
Mar 19, 2025

Incyte EVP Barry Flannelly sells $1.34 million in stock - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Stock market unimpressed by results for Incyte acne drug as share price drops 11% - delawarebusinessnow.com

Mar 19, 2025
pulisher
Mar 19, 2025

Incyte price target lowered to $72 from $74 at Truist - Yahoo Finance

Mar 19, 2025
pulisher
Mar 18, 2025

William Blair Downgrades Incyte (BMV:INCY) - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte EVP Barry Flannelly sells $1.34 million in stock By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 18, 2025

William Blair Downgrades Incyte (BIT:1INCY) - Nasdaq

Mar 18, 2025
$20.34
price up icon 0.39%
$71.65
price up icon 1.40%
$32.28
price up icon 0.14%
$30.31
price up icon 8.55%
$111.97
price up icon 6.59%
biotechnology ONC
$251.60
price down icon 0.80%
Capitalizzazione:     |  Volume (24 ore):